Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Valiant

“One of the most impressive designs we’ve encountered in quite a while”: Valiant Mercury Distressed review

A guitar built in Ukraine that nods to the familiar yet brims with ideas to set it apart from the mundane

Guitar World

10 Greatest and Most Undervalued Key Comics You Should Snatch Up Now

Some of the most underrated and undervalued key comics are not #1 issues. They don’t always feature the first appearances of major characters. Some key comics fall under the radar and are not seen for having the value they should really have. These are key comics you should snatch up…

Personal Finance Advice

Legendary comic writer and editor Jim Shooter, creator of Secret Wars and writer of Avengers, Superman, and more dies at 73

Jim Shooter was once the editor-in-chief of Marvel Comics and pioneered the idea of the superhero crossover

GamesRadar

From analysis to the latest developments in health,
read the most diverse news in one place.

Aston Martin to build Fernando Alonso-commissioned sportscar

Aston Martin is to build a road-legal, track-focussed version of its Valour sportscar – the Valiant – that has been personally commissioned by its Formula 1 driver Fernando Alonso.

Motorsport

Aston Martin to build Alonso-commissioned sportscar

Aston Martin is to build a road-legal track version of its Valour sportscar – the Valiant – that has been personally commissioned by its Formula 1 driver Fernando Alonso.

Autosport

Could a car be any more muscular? Aston Martin unleashes the bold and brutalist Valiant

Equipped with a V12 engine, manual gearbox and chiselled bodywork, the limited-edition Aston Martin Valiant is the company’s most extreme front-engined road car to date

Wallpaper

The best female superheroes

Who are the best female superheroes in comic book history?

GamesRadar

Read news from The Economist, FT, and more,
with one subscription

Apellis Begins Paitent Dosing In Late-Stage Study Of Rare Kidney Disease Candidate

Apellis Pharmaceuticals (NASDAQ: APLS) has dosed first patient in the VALIANT Phase 3 clinical study of its drug candidate Pegcetacoplan for primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G), two rare and debilitating kidney diseases with similar underlyin

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Apellis Pharmaceuticals

17 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.